Brexpiprazole (Synonyms: OPC 34712) |
رقم الكتالوجGC11186 |
Brexpiprazole (OPC-34712) ، دواء مضاد للذهان غير نمطي نشط عن طريق الفم ، هو ناهض جزئي لمستقبلات الإنسان 5-HT1A والدوبامين D2L مع Kis من 0.12 نانومتر و 0.3 نانومتر ، على التوالي
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 913611-97-9
Sample solution is provided at 25 µL, 10mM.
Brexpiprazole is a potent antagonist effects on 5-HT2A, α1B-, and α2C-adrenergic receptors and a partial agonist at serotonin 1A (5-HT1A) and D2 receptors. [1]
5-HT1A receptor is a G protein-coupled receptor that can mediates inhibitory neurotransmission by binding the endogenous neurotransmitter serotonin5-HT. And D2 receptor is a G protein-coupled receptor inhibits adenylyl cyclase activity.
In cloned receptor systems, brexpiprazole displayed partial agonist at h5-HT1A and hD2 receptors, and potent antagonism of h5-HT2A receptors and hα1B/2C-adrenoceptors. [2] When tested in PC12 cells, brexpiprazole increased the number of cells with neurites in a concentration-dependent manner through 5-HT1A receptors and 5-HT2A receptors.[3]
In the dizocilpine-induced social recognition deficits mice model, brexpiprazole (0.01, 0.03, 0.1mg/kg,p.o.) significantly ameliorated the recognition deficits, and had no effect on social recognition in untreated control mice. Brexpiprazole may confer a beneficial effect on social cognition deficits in patients with psychiatric disorders. [1]
References:
[1]. Noriko Yoshimi, Takashi Futamura, Kenji Hashimoto. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. European Neuropsychopharmacology, http://dx.doi.org/10.1016/j.euroneuro.2014.12.014
[2]. Maeda K, Sugino H, Akazawa H et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. journal of pharmacology and experimental therapeutics, 2014 Sep;350(3):589-604.
[3]. Tamaki Ishima, Takashi Futamura, Yuta Ohgi et al. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin–dopamine activity modulator: A role for serotonin 5-HT1A and 5-HT2A receptors. European Neuropsychopharmacology, http://dx.doi.org/10.1016/j.euroneuro.2015.01.014
Cell experiment: |
PC12 cells are cultured at 37°C, 5% CO2 in Dulbecco's modified Eagle's medium (DMEM), supplemented with 5% heat-inactivated fetal bovine serum (FBS),10% heat-inactivated horse serum, and 1% penicillin-streptomycin. Medium is changed two to three times a week. PC12 cells are plated onto 24- well tissue culture plates coated with poly-D-lysine/laminin. Cells are plated at relatively low density (0.25×104 cells/cm2) in DMEM medium containing 0.5% FBS,1% penicillin-streptomyc in Medium containing a minimal level of serum (0.5% FBS) is used. In this study, 2.5 ng/mL of NGF is used to study the potentiating effects of Brexpiprazole on neurite outgrowth. Twenty-four hours after plating, the medium is replaced with DMEM medium containing 0.5% FBS and 1% penicillin-streptomycin with NGF (2.5 ng/mL), with or without Brexpiprazole (0.001,0.01,0.1 or 1 μM), WAY-100,635 (5-HT1A receptor antagonist;10 μM), raclopride (dopamine D2 receptor antagonist;10 μM), DOI (5-HT2A receptor agonist;0.1,1 or 10 μM), M100,907 (5-HT2A receptor antagonist; 0.1, 1 or 10 μM), xestospongin C (IP3 receptor antagonist; 1 μM), 2-APB (IP3 receptor antagonist;100 μM), fluoxetine (5-HT transporter inhibitor: 1 μM), or paroxetine (5-HT transporter inhibitor: 1 μM). Four days after incubation with NGF (2.5ng/mL) with or without specified drugs, morphometric analysis is performed on digitized images of live cells taken under phase-contrast illumination, with an inverted microscope linked to a camera. Images of three fields per well are taken, with an average of 100 cells per field. Differentiated cells are counted by visual examination of the field; only cells that had at least one neurite with a length equal to the cell body diameter are counted, and are then expressed as a percentage of the total cells in the field. Counting is performed in ablinded manner[1]. |
Animal experiment: |
Mice[2] Male C57BL/6NCrSlc mice aged between 4 and 5 weeks old are selected as stranger mice, while animals between 8 and 10 weeks old are used for this study. All mice are housed in groups of five percage, in a room maintained at 23±2°C and 60±10% humidity, with a 12/12h light/dark cycle (lights on at 7:00 a.m.).The mice are given free access to food and water. Brexpiprazole is dissolved in 5% (w/v) gum Arabic and administered orally (p.o.), at 10 mL/kg, 1 h prior to sociability testing. The doses of antipsychotic drugs are selected based on doses that did not impact locomotion. |
References: [1]. Ishima T, et al. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol. 2015 Apr;25(4):505-11. |
Cas No. | 913611-97-9 | SDF | |
المرادفات | OPC 34712 | ||
Chemical Name | 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one | ||
Canonical SMILES | C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4 | ||
Formula | C25H27N3O2S | M.Wt | 433.57 |
الذوبان | ≥ 21.68mg/mL in DMSO with gentle warming | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.3064 mL | 11.5322 mL | 23.0643 mL |
5 mM | 0.4613 mL | 2.3064 mL | 4.6129 mL |
10 mM | 0.2306 mL | 1.1532 mL | 2.3064 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 5 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *